Phase 1 N=44 A Study of Vonoprazan in Adults With Helicobacter Pylori
Helicobacter Pylori
Primary: Cmax: Maximum Observed Plasma Concentration for Bismuth — 42.8; 32.9 nanogram per milliliter (ng/mL)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=10 Continuous Glucose Monitoring During and After Surgery
Diabetes
Primary: Safety and Feasibility Evaluation - Number of Unanticipated Safety Issues — 0 Number of unanticipated safety events
N/A N=167 Cranberry Effect on Urinary Tract Infections
Urinary Tract Infections
Primary: The Incidence of UTI — 66; 54 Participants — p=0.299
N/A N=115 Suicide Prediction and Prevention for People at Risk for Opioid Use Disorder: Supplement to COMPUTE 2.0
Opioid Use · Opioid-use Disorder · Suicide
Primary: Number of Participants With CSSRS Completion on the Same Day or in the 14 Days Following Any Outpatient Visit — 14; 8 Participants
Phase 3 N=116 Total Knee Arthroplasty (TKA) Study of HTX-011 in an Multimodal Analgesic Regimen (MMA) Regimen
Analgesia
Primary: Mean Area Under the Curve (AUC) of the Visual Analogue Scale (VAS). — 155.57; 185.27; 161.36; 126.59 pain intensity score*hr
Phase 2 N=227 A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease
Huntington Disease
Primary: Change From Baseline in Modified Motor Score (mMS) (Sum of Score of Items 4-10 and 13-15 of the UHDRS Motor Assessments) at Week 12 — -1.40; -1.30; -2.49; -2.32 units on…
Phase 3 N=236 An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Participants Who Participated in Prior Roche and Genentech Sponsored Studies
Huntington Disease
Primary: Percentage of Participants With Treatment Emergent Adverse Events — 71.4; 83.9; 81.8 Percentage of Participants
Phase 2 N=60 Low Dose ICG for Biliary Tract and Tumor Imaging
Cholecystitis · Hepatocellular Carcinoma · Liver Metastases
Primary: Quantitative Assessment - Bile Duct-to-liver Fluorescence Intensity Ratio — 2.7; 0.7 ratio
N/A N=273 Protecting Our Community: COVID-19 Testing
SARS-CoV-2 · Covid19
Primary: SARS-CoV-2 Home-testing Kit Completion Active vs. Passive Arms — 75; 94; 57; 42 Participants — p=0.04
N/A N=65 Engaging Families to Improve the Care of Patients With Hypospadias
Hypospadias
Primary: Percent of Eligible Parents Screened (Feasibility) — 90.5 percentage of parents recruited
Phase 3 N=107 DE-117 Spectrum 5 Study
Primary Open-angle Glaucoma and Ocular Hypertension
Primary: Change From Baseline in Mean Diurnal Intraocular Pressure (IOP) at Month 3. — -2.96 mmHg
N/A N=55 Overlapping Neural Circuits in Pediatric OCD
Obsessive Compulsive Disorder
Primary: Brain Activation Associated With the Resolution of Cognitive Conflict — .7; .59 Arbitrary units — p=0.0585
Phase 3 N=426 A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 Study
Glaucoma and Ocular Hypertension
Primary: Intraocular Pressure at Week 1 — 19.0; 19.1; 18.0; 18.2 mmHg
Phase 2 N=20 Lubiprostone as a Modulator of Gut Microbial Translocation in HIV With Incomplete CD4 Recovery on Antiretroviral Therapy
HIV
Primary: Changes in Gut Microbial Translocation (iFABP) — 145.76; 125.36; 151.5; 111.73 pg/mL
N/A N=100 Reversing Synchronized Brain Circuits With Targeted Auditory-Somatosensory Stimulation to Treat Phantom Percepts
Tinnitus
Primary: Change in Objective Tinnitus Loudness — -6.1; -9.5; -10.2; -11.0 decibels sensation level (dB SL)